A 24-Week, Multi-Center, Randomized, Open-Label Clinical Trial Comparing the Effects of Xuezhikang and Atorvastatin on Glucose Metabolism in Patients with Dyslipidemia and Prediabetes (XTREME Study): Design of the Study Protocol

A 24-Week, Multi-Center, Randomized, Open-Label Clinical Trial Comparing the Effects of Xuezhikang and Atorvastatin on Glucose Metabolism in Patients with Dyslipidemia and Prediabetes (XTREME Study): Design of the Study Protocol

Background: Statins, a first-line therapeutic option for atherosclerotic cardiovascular disease (ASCVD), have prompted concerns regarding dysglycemia and diabetes, thus posing a dilemma in treating patients with prediabetes. Xuezhikang (XZK) decreases blood cholesterol levels without affecting gluc...

Full description

Saved in:
Bibliographic Details
Main Authors: Lan Fu, Yiqun Zhang, Xin Du, Rong Han, Rong Hu, Craig S. Anderson, Linong Ji, Changsheng Ma
Format: Article
Language:English
Published: Compuscript Ltd 2024-01-01
Series:Cardiovascular Innovations and Applications
Online Access:https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0010
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items